Trials / Completed
CompletedNCT00443144
D3-GHR Polymorphism and Turner Syndrome
D3-Growth Hormone Receptor Polymorphism and Total Effect of Recombinant Human Growth Hormone on Growth in Girls With Turner Syndrome
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- —
- Sponsor
- University Hospital Tuebingen · Academic / Other
- Sex
- Female
- Age
- 38 Months – 14 Years
- Healthy volunteers
- —
Summary
The protein polymorphism of the growth hormone receptor characterized by the genomic deletion of exon 3 has been linked to the magnitude of the first-year-growth response to growth hormone (GH) in girls with Turner syndrome. Objective: to study the long-term effect of GH therapy in Turner syndrome in correlation to this GHR polymorphism in a mainly retrospective design (chart-review).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | recombinant human growth hormone |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2007-04-01
- Completion
- 2007-05-01
- First posted
- 2007-03-05
- Last updated
- 2015-12-03
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00443144. Inclusion in this directory is not an endorsement.